Published in Oncotarget on July 18, 2017
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A (2011) 10.56
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature (2015) 5.15
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (2015) 4.88
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One (2012) 3.14
Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol (2014) 2.87
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med (2016) 2.54
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol (2014) 2.23
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 2.19
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol (2014) 1.77
From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol (2013) 1.55
Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods (2014) 1.55
A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol (2016) 1.53
Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies. J Nucl Med (2015) 1.51
Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol (2015) 1.45
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov (2016) 1.37
CANCER IMMUNOLOGY. The "cancer immunogram". Science (2016) 1.27
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun (2015) 1.25
The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother (2012) 1.20
Noninvasive imaging of immune responses. Proc Natl Acad Sci U S A (2015) 1.20
Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci U S A (2011) 1.19
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia (2014) 1.17
Biomarkers in cancer immunotherapy. Cancer Cell (2015) 1.16
Platelets at the interface of thrombosis, inflammation, and cancer. Blood (2015) 1.11
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat (2014) 1.08
Real-time liquid biopsies become a reality in cancer treatment. Ann Transl Med (2015) 1.07
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol (2015) 1.06
Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget (2014) 1.05
Development of an innovative 3D cell culture system to study tumour--stroma interactions in non-small cell lung cancer cells. PLoS One (2014) 1.03
Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J Transl Med (2012) 0.99
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget (2015) 0.97
An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. Cancer Res (2015) 0.96
Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J Immunother Cancer (2015) 0.95
Harmonization: the sample, the measurement, and the report. Ann Lab Med (2014) 0.95
Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol (2016) 0.94
Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol (2017) 0.94
Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med (2015) 0.91
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). Clin Cancer Res (2016) 0.90
Characterization of RNA from Exosomes and Other Extracellular Vesicles Isolated by a Novel Spin Column-Based Method. PLoS One (2015) 0.89
Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer (2017) 0.88
MYC quantitation in cell-free plasma DNA by real-time PCR for gastric cancer diagnosis. Clin Chem Lab Med (2009) 0.87
CANCER. The odds of immunotherapy success. Science (2015) 0.86
The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy (2016) 0.86
High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Eur J Cancer (2016) 0.85
Cell-free circulating tumor DNA in cancer. Chin J Cancer (2016) 0.85
HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study. Gastric Cancer (2014) 0.85
Developing proteomic biomarkers for bladder cancer: towards clinical application. Nat Rev Urol (2015) 0.84
Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma. Gynecol Oncol (2013) 0.84
Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2. Anticancer Res (2011) 0.84
Prediction of response in cancer immunotherapy. Anticancer Res (2011) 0.84
Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. J Immunother Cancer (2014) 0.83
Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates. Gynecol Oncol (2015) 0.83
Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems. Transl Res (2016) 0.82
Grading breast cancer tissues using molecular portraits. Mol Cell Proteomics (2013) 0.82
PD-L1 expression as a potential predictive biomarker. Lancet Oncol (2015) 0.82
Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice. Curr Cancer Drug Targets (2015) 0.82
Imaging Biomarkers in Immunotherapy. Biomark Cancer (2016) 0.81
Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery. Expert Rev Proteomics (2016) 0.81
Pathologists and liquid biopsies: to be or not to be? Virchows Arch (2016) 0.81
Clonal cytotoxic T cells in myeloma. Leuk Lymphoma (2003) 0.80
Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. Br J Cancer (2015) 0.80
Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. Ann Oncol (2016) 0.80
Cancer Metabolomics and the Human Metabolome Database. Metabolites (2016) 0.80
Infiltration of lymphocyte subpopulations into cancer microtissues as a tool for the exploration of immunomodulatory agents and biomarkers. Immunobiology (2016) 0.80
Next generation biomarkers in prostate cancer. Front Biosci (Landmark Ed) (2016) 0.80
Proteomic analysis of exosomal cargo: the challenge of high purity vesicle isolation. Mol Biosyst (2016) 0.79
A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma. Int J Proteomics (2015) 0.79
Emerging Role of MicroRNAs as Liquid Biopsy Biomarkers in Gastrointestinal Cancers. Clin Cancer Res (2017) 0.79
Vesicle-MaNiA: extracellular vesicles in liquid biopsy and cancer. Curr Opin Pharmacol (2016) 0.78
Liquid biopsy for early detection of lung cancer. Curr Opin Oncol (2017) 0.78
Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics. Ann N Y Acad Sci (2015) 0.77
Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis. Mol Oncol (2016) 0.77
Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses. Clin Cancer Res (2016) 0.76
Inflammasome in platelets: allying coagulation and inflammation in infectious and sterile diseases? Mediators Inflamm (2015) 0.76
Building a roadmap to biomarker qualification: challenges and opportunities. Biomark Med (2015) 0.76
The future of patient-derived tumor xenografts in cancer treatment. Pharmacogenomics (2015) 0.76
Hunting for the ultimate liquid cancer biopsy - let the TEP dance begin. Cell Commun Signal (2016) 0.76
Recent advances in salivary cancer diagnostics enabled by biosensors and bioelectronics. Biosens Bioelectron (2016) 0.76
Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective. Arch Pathol Lab Med (2016) 0.76
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Trends Pharmacol Sci (2016) 0.75
Liquid biopsy genotyping in lung cancer: ready for clinical utility? Oncotarget (2017) 0.75
The feasibility of using mutation detection in ctDNA to assess tumor dynamics. Int J Cancer (2017) 0.75
Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients. PLoS One (2016) 0.75
Circulating Tumor Cells: Fluid Surrogates of Solid Tumors. Annu Rev Pathol (2017) 0.75
Advancing the global proteome survey platform by using an oriented single chain antibody fragment immobilization approach. N Biotechnol (2015) 0.75
Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy. Trends Pharmacol Sci (2016) 0.75
Bringing 3D tumor models to the clinic - predictive value for personalized medicine. Biotechnol J (2017) 0.75
Liquid biopsy: its impact on cancer diagnostics. MLO Med Lab Obs (2015) 0.75
Liquid Biopsies, What We Do Not Know (Yet). Cancer Cell (2017) 0.75
therascreen (®) EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer. Mol Diagn Ther (2016) 0.75
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res (2014) 1.08
Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium. J Extracell Vesicles (2015) 1.02
Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma. Oncotarget (2016) 0.78
B7-H abnormalities in melanoma and clinical relevance. Methods Mol Biol (2014) 0.78
Disentangling the relationship between tumor genetic programs and immune responsiveness. Curr Opin Immunol (2016) 0.77
Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization. Oncotarget (2016) 0.75
Successful adaption of a forensic toxicological screening workflow employing nontargeted liquid chromatography-tandem mass spectrometry to water analysis. Electrophoresis (2016) 0.75
Multiparametric immune profiling in HPV- oral squamous cell cancer. JCI Insight (2017) 0.75
Compound identification in forensic toxicological analysis with untargeted LC-MS-based techniques. Bioanalysis (2015) 0.75
Linking CREB function with altered metabolism in murine fibroblast-based model cell lines. Oncotarget (2017) 0.75
Leoligin, the major lignan from Edelweiss, inhibits 3-hydroxy-3-methyl-glutaryl-CoA reductase and reduces cholesterol levels in ApoE-/- mice. J Mol Cell Cardiol (2016) 0.75